Tacrolimus (FK506) suppresses rt-PA-induced hemorrhagic transformation in a rat thrombotic ischemia stroke model

Brain Research

Volumn 1254, Issue , 2009, Pages 99-108

  Maeda, Masashi ^a   Furuichi, Yasuhisa ^a   Noto, Takahisa ^a   Matsuoka, Nobuya ^a   Mutoh, Seitaro ^a   Yoneda, Yukio ^b  

^a ASTELLAS PHARMA INC   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

Author keywords

Combination therapy; Cytoprotection; Hemorrhagic transformation; Microvascular endothelial cell; Recombinant tissue plasminogen activator; Thrombotic occlusion

Indexed keywords

CD31 ANTIGEN; EVANS BLUE; IMMUNOSUPPRESSIVE AGENT; RECOMBINANT PROTEIN; TACROLIMUS; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN; CEREBRAL ARTERY DISEASE; DRUG EFFECT; ENDOTHELIUM CELL; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MICROVASCULATURE; PATHOPHYSIOLOGY; RAT; SPONTANEOUSLY HYPERTENSIVE RAT;

ANIMALS; ANTIGENS, CD31; BLOOD-BRAIN BARRIER; BRAIN; ENDOTHELIAL CELLS; EVANS BLUE; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; MICROVESSELS; RATS; RATS, INBRED SHR; RECOMBINANT PROTEINS; TACROLIMUS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 58549083332     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2008.11.080     Document Type: Article

References (30)

1. Aronowski J., Strong R., Shirzadi A., and Grotta J.C. Ethanol plus caffeine (caffeinol) for treatment of ischemic stroke: preclinical experience. Stroke 34 (2003) 1246-1251
2. Bevilacqua M.P. Endothelial-leukocyte adhesion molecules. Annu. Rev. Immunol. 11 (1993) 767-804
3. Cuadrado E., Ortega L., Hernandez-Guillamon M., Penalba A., Fernandez-Cadenas I., Rosell A., and Montaner J. Tissue plasminogen activator (t-PA) promotes neutrophil degranulation and MMP-9 release. J. Leukoc. Biol. 7 (2008) 7
4. del Zoppo G.J., Poeck K., Pessin M.S., Wolpert S.M., Furlan A.J., Ferbert A., Alberts M.J., Zivin J.A., Wechsler L., Busse O., et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann. Neurol. 32 (1992) 78-86
5. Furuichi Y., Katsuta K., Maeda M., Ueyama N., Moriguchi A., Matsuoka N., Goto T., and Yanagihara T. Neuroprotective action of tacrolimus (FK506) in focal and global cerebral ischemia in rodents: dose dependency, therapeutic time window and long-term efficacy. Brain Res. 965 (2003) 137-145
6. Furuichi Y., Maeda M., Moriguchi A., Sawamoto T., Kawamura A., Matsuoka N., Mutoh S., and Yanagihara T. Tacrolimus, a potential neuroprotective agent, ameliorates ischemic brain damage and neurologic deficits after focal cerebral ischemia in nonhuman primates. J. Cereb. Blood Flow Metab. 23 (2003) 1183-1194
7. Furuichi Y., Noto T., Li J.Y., Oku T., Ishiye M., Moriguchi A., Aramori I., Matsuoka N., Mutoh S., and Yanagihara T. Multiple modes of action of tacrolimus (FK506) for neuroprotective action on ischemic damage after transient focal cerebral ischemia in rats. Brain Res. 1014 (2004) 120-130
8. Furuichi Y., Maeda M., Matsuoka N., Mutoh S., and Yanagihara T. Therapeutic time window of tacrolimus (FK506) in a nonhuman primate stroke model: comparison with tissue plasminogen activator. Exp. Neurol. 204 (2007) 138-146
9. Goto H., Fujisawa H., Oka F., Nomura S., Kajiwara K., Kato S., Fujii M., Maekawa T., and Suzuki M. Neurotoxic effects of exogenous recombinant tissue-type plasminogen activator on the normal rat brain. J. Neurotrauma 24 (2007) 745-752
10. Hacke W., Kaste M., Fieschi C., Toni D., Lesaffre E., von Kummer R., Boysen G., Bluhmki E., Hoxter G., Mahagne M.H., et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). Jama 274 (1995) 1017-1025
11. Hacke W., Kaste M., Fieschi C., von Kummer R., Davalos A., Meier D., Larrue V., Bluhmki E., Davis S., Donnan G., Schneider D., Diez-Tejedor E., and Trouillas P. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 352 (1998) 1245-1251
12. Hamann G.F., Liebetrau M., Martens H., Burggraf D., Kloss C.U., Bultemeier G., Wunderlich N., Jager G., and Pfefferkorn T. Microvascular basal lamina injury after experimental focal cerebral ischemia and reperfusion in the rat. J. Cereb. Blood Flow Metab. 22 (2002) 526-533
13. Hamann G.F., Schrock H., Burggraf D., Wunderlich N., Liebetrau M., and Kuschinsky W. Microvascular Basal lamina damage after embolic stroke in the rat: relationship to cerebral blood flow. J. Cereb. Blood Flow Metab. 23 (2003) 1293-1297
14. Kaste M. Thrombolysis in ischaemic stroke - present and future: role of combined therapy. Cerebrovasc. Dis. 11 Suppl 1 (2001) 55-59
15. Kirsch T., Wellner M., Luft F.C., Haller H., and Lippoldt A. Altered gene expression in cerebral capillaries of stroke-prone spontaneously hypertensive rats. Brain Res. 910 (2001) 106-115
16. Maeda M., Furuichi Y., Ueyama N., Moriguchi A., Satoh N., Matsuoka N., Goto T., and Yanagihara T. A combined treatment with tacrolimus (FK506) and recombinant tissue plasminogen activator for thrombotic focal cerebral ischemia in rats: increased neuroprotective efficacy and extended therapeutic time window. J. Cereb. Blood Flow Metab. 22 (2002) 1205-1211
17. Matsuno H., Uematsu T., Umemura K., Takiguchi Y., Asai Y., Muranaka Y., and Nakashima M. A simple and reproducible cerebral thrombosis model in rats induced by a photochemical reaction and the effect of a plasminogen-plasminogen activator chimera in this model. J. Pharmacol. Toxicol. Methods 29 (1993) 165-173
18. Migita K., Maeda Y., Abiru S., Nakamura M., Komori A., Yokoyama T., Takii Y., Mori T., Yatsuhashi H., Eguchi K., and Ishibashi H. Immunosuppressant FK506 inhibits matrix metalloproteinase-9 induction in TNF-alpha-stimulated human hepatic stellate cells. Life Sci. 78 (2006) 2510-2515
19. Mori A., Tanaka J., Kobayashi S., Hashino S., Yamamoto Y., Ota S., Asaka M., and Imamura M. Fatal cerebral hemorrhage associated with cyclosporin-A/FK506-related encephalopathy after allogeneic bone marrow transplantation. Ann. Hematol. 79 (2000) 588-592
20. Okubo S., Igarashi H., Kanamatsu T., Hasegawa D., Orima H., and Katayama Y. FK-506 extended the therapeutic time window for thrombolysis without increasing the risk of hemorrhagic transformation in an embolic rat stroke model. Brain Res. 1143 (2007) 221-227
21. Pizzolato G.P., Sztajzel R., Burkhardt K., Megret M., and Borisch B. Cerebral vasculitis during FK 506 treatment in a liver transplant patient. Neurology 50 (1998) 1154-1157
22. Romanic A.M., and Madri J.A. Extracellular matrix-degrading proteinases in the nervous system. Brain Pathol. 4 (1994) 145-156
23. Rosen G.D., and Harry J.D. Brain volume estimation from serial section measurements: a comparison of methodologies. J. Neurosci. Methods 35 (1990) 115-124
24. Sharkey J., and Butcher S.P. Immunophilins mediate the neuroprotective effects of FK506 in focal cerebral ischaemia. Nature 371 (1994) 336-339
25. Siao C.J., and Tsirka S.E. Extracellular proteases and neuronal cell death. Cell. Mol. Biol. (Noisy-le-grand) 48 (2002) 151-161
26. Tsirka S.E., Rogove A.D., Bugge T.H., Degen J.L., and Strickland S. An extracellular proteolytic cascade promotes neuronal degeneration in the mouse hippocampus. J. Neurosci. 17 (1997) 543-552
27. Uyama O., Okamura N., Yanase M., Narita M., Kawabata K., and Sugita M. Quantitative evaluation of vascular permeability in the gerbil brain after transient ischemia using Evans blue fluorescence. J. Cereb. Blood Flow Metab. 8 (1988) 282-284
28. Vosko M.R., Busch E., Burggraf D., Bultemeier G., and Hamann G.F. Microvascular basal lamina damage in thromboembolic stroke in a rat model. Neurosci. Lett. 353 (2003) 217-220
29. Warlow C.P. Epidemiology of stroke. Lancet 352 Suppl 3 (1998) SIII1-SIII4
30. Zawadzka M., and Kaminska B. A novel mechanism of FK506-mediated neuroprotection: downregulation of cytokine expression in glial cells. Glia 49 (2005) 36-51